Impact of New Therapeutics for Hepatitis C Virus Infection in Incarcerated Populations
Author: Anne C. Spaulding, MD, MPH .; Arthur Y. Kim, MD.; Amy Jo Harzke, DrPH.; Jean C. Sullivan, JD.; Benjamin P. Linas, MD, MPH.
Source: Volume 15, Number 04, May/June 2014 , pp.51-54(4)
< previous article |next article > |return to table of contents
Abstract:
In Part I of this article, the distinguished authors presented the dimensions of the HCV infection in correctional settings, and it is a problem of considerable dimension, along with a listing of antiviral treatment. Newer therapies shorten the length of stay requirement and increase the cost of care, presently a cost-efficiency conundrum for correctional officials. Part II, which follows, focuses on the emerging and future therapies.Keywords: triple therapy; oral DAAs; Project ECHO; community viral load; high-risk behavior; cost-effectiveness ratio; screening; HIV co-infection; fibrosis; cirrhosis; ESLD; transplant
Affiliations:
1: Emory University; 2: Harvard Medical School; 3: University of Texas, Medical Branch; 4: University of Massachusetts Medical School; 5: Boston University School of Medicine.